Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
Profound Medical (NASDAQ:PROF; TSX:PRN), a commercial-stage medical device company, announced its upcoming participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference. The company, which specializes in developing customizable, incision-free therapies for diseased tissue ablation, will present a business update on Tuesday, May 6, 2025, at 1:30 p.m. Eastern Time.
The presentation will take place at the Metro Toronto Convention Centre. Investors and interested parties can access the live broadcast and archived recording through the "Webcasts" section under Investors on the company's website at www.profoundmedical.com.
Positive
- Presentation at a major healthcare investor conference indicates active investor relations and potential visibility to institutional investors
- Company maintains commercial-stage status with marketed medical device products
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PROF declined 3.21%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre.
The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
When is Profound Medical (PROF) presenting at the 2025 Bloom Burton Healthcare Conference?
How can I watch Profound Medical's (PROF) 2025 Bloom Burton Conference presentation?
What type of medical technology does Profound Medical (PROF) develop?
Where is Profound Medical's (PROF) 2025 Bloom Burton Conference presentation taking place?
Which stock exchanges is Profound Medical (PROF) listed on?
